Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
4DMT Reports Positive Interim Data for Wet AMD Treatment
4D Molecular Therapeutics (4DMT) announced positive interim data from the Phase 2 PRISM clinical trial, marking a significant stride in the treatment of wet age-related macular degeneration (wet AMD). Arshad M. Khanani, MD, MA, FASRS, presented the data at the…
Reginald J. Sanders, M.D. Named as New President of the ASRS
Dr. Reginald J. Sanders, a distinguished physician affiliated with the Retina Group of Washington (RGW) and PRISM Vision Group, has been named as the new president of the American Society of Retina Specialists (ASRS). Dr. Sanders holds the distinction of…
Mireca Medicines Gets $1M Boost for Retinal Disease Treatment
Mireca Medicines has been awarded a $989,000 ‘Translational Research Acceleration Program Award’ from the Foundation Fighting Blindness, enabling the company to advance preclinical development of its lead product, MM238. Recognizing Mireca’s pivotal role in targeting the cGMP pathway for treating…
WCO and CooperVision Host Myopia Management Event in LATAM
In a strategic move to advance myopia management as the standard of care, the World Council of Optometry (WCO) has teamed up with CooperVision to host its inaugural Latin America-based virtual event, “Myopia Management: From Theory to Practice.” Scheduled for…
Hearing Loss is Rare in Tepezza Treatment for TED
A recent study, led by Dr. Raymond Douglas, MD, PhD, revealed that long-term hearing loss is a rare occurrence in individuals with normal audiometry at baseline following treatment with Tepezza [teprotumumab]. Published in the current issue of the prestigious journal…
Explained: How Long Is Ophthalmology Residency?
Embarking on a career in ophthalmology involves a meticulous journey of education and training, with the residency period being a critical phase in shaping a future ophthalmologist’s expertise. The duration of an ophthalmology residency is a key consideration for aspiring…
DigitalOptometrics Launches Real-Time Translation Service
DigitalOptometrics has unveiled a revolutionary solution to enhance patient care with the launch of “DOT” (DigitalOptometrics Translate), a real-time translation service designed to break down language barriers in the optometric industry. The innovative “DOT” technology facilitates seamless communication between eye…
Aviceda Launches Phase 2 Clinical Trial for AVD-104
Aviceda Therapeutics announced a significant milestone in the development of its lead ophthalmic candidate, AVD-104, with the enrollment of the first patient in the GLYCO phase 2 US clinical trial. The trial aims to evaluate the efficacy and safety of…
FDA Approves ZEISS’ VISUMAX® 800 for Nearsightedness
The FDA has approved the VISUMAX® 800 equipped with SMILE® pro software from ZEISS. This state-of-the-art femtosecond laser technology is designed for the surgical treatment of nearsightedness, with or without astigmatism. The VISUMAX® 800 enters the U.S. market at a…
Ocuphire Pharma Gets FDA Nod for Dim Light Visual Acuity Trial
In a recent announcement, Ocuphire Pharma disclosed that it has secured approval from the U.S. Food and Drug Administration (FDA) under a special protocol assessment (SPA) for the clinical trial protocol and planned statistical analysis of its LYNX-2 phase 3…